BLBarry K. Logan

Barry K. Logan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Barry K. Logan has a total of 241 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quantification of kratom alkaloids mitragynine, 7-hydroxy mitragynine, mitragynine pseudoindoxyl, and dihydro-7-hydroxy mitragynine in forensic casework and medicolegal death investigations

    by Lauren K Eccarius, Sara E Walton, Donna M Papsun, Barry K Logan, Alex J Krotulski

    Mitragynine (MG) is the primary psychoactive component of the kratom plant (Mitragyna speciosa). 7-Hydroxy mitragynine (7OH-MG) is found naturally in the plant but in small amounts (<2%). MG is metabolized to 7OH-MG and further to mitragynine pseudoindoxyl (MP), with the latter documented via in vitro enzymatic activity. Lack of scheduling and oversight has caused unregulated markets to proliferate with gas stations, smoke shops, and online retailers selling semi-synthetic formulations of these alkaloids under the umbrella term “kratom,” though distinct from botanical kratom. Products containing 7OH-MG, MP, and synthetically derived dihydro-7-hydroxy mitragynine (DH-7OH-MG, aka MGM-15) exhibit greater potencies and activities at the µ-opioid receptor compared to MG and are now highly implicated in intoxications and deaths. These alkaloids present complex analytical and interpretive challenges due to their isomeric forms, incompatibility with certain extraction and instrumental techniques promoting analyte interconversion, instability in blood, and lack of published concentration ranges. A quantitative high-resolution mass spectrometry method for MG, 7OH-MG, MP, and DH-7OH-MG, which prevents interconversion and separates isomers, is presented herein along with stability data and concentrations from more than 200 authentic cases. MG, MP, and DH-7OH-MG were relatively stable in blood, whereas 7OH-MG decreased quickly and by 89% over 112 days with a concurrent increase in MP. In a case subset (n = 139), mean ± SD concentrations in blood were 146 ± 477 ng/ml for 7OH-MG (median: 58 ng/ml, range: 0–5000 ng/ml) and 194 ± 239 ng/ml for MP (median: 120 ng/ml, range: 4.8–1900 ng/ml). In a second subset (n = 17), the mean ± SD DH-7OH-MG (MGM-15) concentration was 324 ± 669 ng/ml (median: 170 ng/ml, range: 50–2900 ng/ml). Testing for kratom alkaloids is currently extremely limited and/or subject to potential inaccuracies due to interconversion, leaving adverse events and fatalities under-investigated. Continued vigilance is needed as the kratom alkaloid product landscape rapidly evolves.

  • Intoxications and fatalities associated with the ingestion of the novel synthetic cathinone, N -isopropyl butylone

    by Munchelou M Gomonit, Sara E Walton, Michael T Truver, Chris W Chronister, Donna M Papsun, Alex J Krotulski, Bruce A Goldberger, Barry K Logan

    Synthetic cathinones represent an expanding class of novel psychoactive substances (NPS), with their proliferation largely driven by international drug control measures and the rapid cycling of structural analogues designed to circumvent legislative scheduling. Following the international control of N, N-dimethylpentylone (DMP) in 2024, N-isopropyl butylone (NiPB) was increasingly detected in forensic toxicological casework as the prevalence of DMP declined. However, limited data currently exist regarding NiPB’s concentration ranges in forensic investigations. This report describes a validated liquid chromatography-tandem quadrupole mass spectrometry (LC-QQQ-MS) method for the quantitation of NiPB in biological specimens, which was applied to the analysis of drugged driving (n = 1) and postmortem (n = 15) cases. The driving under the influence of drugs case yielded a NiPB blood concentration of 16 ng/mL, whereas the remaining 15 cases demonstrated blood concentrations ranging from <1 to 1400 ng/mL. For one case, NiPB was quantitated in blood, vitreous fluid, and urine, with concentrations of 18, 17, and 2200 ng/mL, respectively. Polydrug use was observed for all cases and frequently involved fentanyl (75%), cocaine and/or methamphetamine (69%), other synthetic cathinones (25%), ethanol (31%), and additional NPS such as bromazolam (19%) and MDMB-4en-PINACA (13%). Concentrations overlapped between antemortem and postmortem cases and were comparable to those reported for structurally related beta-keto methylenedioxyamphetamines, suggesting that members of this analogue class may share similar patterns of use and toxicological profiles. Although NiPB was identified as a contributing factor in several fatalities, the lack of pharmacological and toxicological data limits further interpretation of measured concentrations and the extent of its contribution to these fatal outcomes. Additional studies incorporating paired central and peripheral blood specimens are warranted to better characterize potential postmortem redistribution and its impact on NiPB blood concentration interpretation. Overall, this case series addresses a critical literature gap on NiPB by providing analytical and interpretive data to support forensic laboratories as NiPB identifications increase within the evolving NPS stimulant market.

  • Open Access

    Micro‐QuEChERS Extraction for Broad‐Spectrum LC‐QQQ‐MS Quantification of Nitazene Analogs in Plasma: A Validated Method With Casework Application

    by Karla A. O. Souza, Náthaly C. B. F. Santos, Rafael Lanaro, Sara E. Walton, Alex J. Krotulski, Barry K. Logan, Mauricio Yonamine, Jose Luiz Costa

    Nitazenes are highly potent synthetic opioids of increasing concern in clinical and forensic toxicology, thus underscoring the need for sensitive and selective analytical methods for biological specimens. This study describes the development and validation of an LC–MS/MS method for the quantification of nitazene analogs and related metabolites in plasma using micro‐QuEChERS sample preparation. The validated concentration range was 0.05–20 ng/mL, with coefficients of determination R 2 > 0.99. The limit of detection (LOD) was 0.025 ng/mL, and the lower limit of quantification (LLOQ) was 0.05 ng/mL. Bias ranged from −2.6% to 15.7%, within‐run precision from 3.4% to 12.7%, and between‐run precision from 4.4% to 14.9%, as evaluated at three quality control levels. Matrix effects and recovery were analyte‐dependent but compatible with satisfactory overall validation performance. No interferences or carryover were observed. Method applicability was demonstrated in an authentic intoxication case, in which N ‐pyrrolidino protonitazene was quantified at 1.4 ng/mL, representing, to our knowledge, the first clinical case reported in Brazil. The case was clinically characterized by severe opioid toxicity requiring repeated naloxone administration. The proposed method combined low sample volume, simple sample preparation, and suitable analytical performance for targeted analysis of emerging nitazene compounds. These findings support the use of micro‐QuEChERS and LC–MS/MS as a practical approach for targeted nitazene quantification in clinical and forensic toxicology.

  • Drug Detection in Traffic-Related Fatalities in Connecticut (2020-2024)

    by Amanda L A Mohr, James R Gill, Barry K Logan

    Motor vehicle fatalities continue to be a leading cause of preventable death in the United States. Beginning in 2019, there was a steady uptick in traffic fatalities nationally, which peaked in 2021. The state of Connecticut has experienced similar trends with increases in traffic fatalities over the last several years. The focus of this review was to evaluate drug positivity in traffic-related fatalities that occurred in Connecticut between January 1, 2020 and December 31, 2024. Cases related to traffic fatalities were identified by the state’s Office of the Chief Medical Examiner. Deaths of drivers, passengers, and pedestrians were used for the data set. A total of 1,816 fatal motor vehicle incidents were reviewed. Of these, 312 cases lacked toxicology results, and five cases had testing canceled; both were excluded from substance-related analyses. Among the remaining 1,499 cases with available toxicological data, 1,084 (72%) had at least one positive toxicology finding. Drug positivity was identified in 75% (713 of 948) of driver fatalities, 66% (125 of 188) of passenger fatalities, and 67% (221 of 327) of pedestrian fatalities. The most frequently encountered drugs across all three classes of decedents were ethanol, delta-9 tetrahydrocannabinol, and fentanyl. These findings underscore the pervasive role of drugs and alcohol across all categories of traffic-related deaths and highlight the ongoing need for preventive strategies, toxicology testing, and targeted public safety interventions.

  • Comprehensive toxicological characterization and quantitation of drugs identified among nonfatal opioid and stimulant overdose presentations to US emergency departments

    by Brianna N Stang, Jessica T Kent, Sara E Walton, Kim Aldy, Rachel Culbreth, Alyssa Falise, Sharan Campleman, Barry K Logan, Jeffrey Brent, Paul Wax, et al.

    Drug overdoses presenting to emergency departments (EDs) remain poorly characterized largely due to limitations resulting from constraints of hospital toxicology testing. This presents significant challenges for forensic and public health communities, as this population of primarily nonfatal overdoses is frequently not included with other data streams (e.g. fatalities, recreational drug markets), producing incomplete national and regional knowledge. To combat this issue, we performed a comprehensive toxicological analysis on patients presenting to EDs with suspected opioid or stimulant overdose. The Toxicology Investigators Consortium (ToxIC) implemented the Drug Toxico-Surveillance Reporting System at 17 healthcare institutions across the United States between April 2023 and September 2024, 995 patients (mortality rate = 1.0%, n = 10) were enrolled, and blood specimens were collected and analyzed at the Center for Forensic Science Research and Education. All specimens underwent blood alcohol analysis, comprehensive screening of over 1,200 xenobiotics, and quantitation for drugs of interest. At least one xenobiotic was detected in 992 specimens. Most frequently observed drugs include fentanyl (n = 713, mean: 8.0 ± 11 ng/mL), methamphetamine (n = 380, mean: 170 ± 210 ng/mL), and cocaine (n = 306, mean: 7.6 ± 15 ng/mL). There were 629 detections of 43 unique novel psychoactive substances (NPS), including potent alpha-2-agonists xylazine (n = 249, mean: 14 ± 29 ng/mL) and medetomidine (n = 31, mean: 1.5 ± 1.8 ng/mL). Regional trends observed include increased prevalence of methamphetamine in the western and central United States, alpha-2-agonists in the eastern United States, and greater NPS diversity in the eastern United States. Traditional opioids and stimulants were generally detected at higher mean concentrations than their more potent NPS counterparts. Quantitative data varies in comparison to literature on postmortem and driving under the influence of drugs cases. This is the first study to analyze blood specimens and provide quantitative data from a large sample of primarily nonfatal opioid/stimulant related overdoses.


  • In vitro metabolic profile characterization for synthetic cannabinoids MDMB-BINACA, MDMB-PICA, and AB-CHMINACA

    by Lauren K Eccarius, Brianna N Stang, Sara E Walton, Alex J Krotulski, Barry K Logan

    The illicit synthetic cannabinoid receptor agonist (SCRA) market has experienced multiple changes since its appearance in the 2010s and, most recently, in response to a class-wide SCRA ban imposed by China in 2021. The reemergence of “older” SCRAs, such as the highly potent indole- and indazole-3-carboxamide-containing drugs, has occurred due to the sale of unregulated precursors on grey-market and dark websites. This shift poses a significant threat to public health, and recent intoxication outbreaks associated with these types of SCRAs demonstrate the need for further toxicological research to aid in better understanding their metabolism and appropriate targets for toxicological testing. Testing for metabolites can extend the detection window of SCRAs as parent drugs are rapidly metabolized and present at low or potentially undetectable concentrations in biological samples, including urine. In these instances, metabolites may be more sensitive biomarkers of SCRA use. This study characterized the metabolites for the synthetic cannabinoids MDMB-BINACA (also known as MDMB-BUTINACA), MDMB-PICA, and AB-CHMINACA via in vitro human liver microsome (HLM) incubation and analysis by liquid chromatography–quadrupole time-of-flight mass spectrometry (LC–QTOF-MS). Biotransformations observed in this study included ester and amide hydrolysis, oxidation, carboxylation, and dealkylation. Nine metabolites were identified for MDMB-BINACA, five of which were verified through retrospective analysis of authentic samples. Nine metabolites were also identified for both MDMB-PICA and AB-CHMINACA, with two metabolites of AB-CHMINACA verified in authentic samples. Characterization of the metabolism of these potent drugs allows for the use of the identified biomarker to improve forensic toxicology analyses and interpretation, especially when the use of synthetic cannabinoids is suspected.


  • Open Access

    Rapid LC–QTOF–MS screening method for semi-synthetic cannabinoids in whole blood

    by Willi Schirmer, Sara E Walton, Wolfgang Weinmann, Stefan Schürch, Barry K Logan, Alex J Krotulski

    Semi-synthetic cannabinoids are a class of new psychoactive substances (NPSs) with structural similarities to the main psychoactive phytocannabinoid Δ9-tetrahydrocannabinol (Δ9-THC) found in Cannabis sativa L. The first semi-synthetic cannabinoids, which were used as legal substitutes for marijuana, were Δ8-tetrahydrocannabinol (Δ8-THC) and hexahydrocannabinol (HHC). Δ8-THC emerged around 2019 on the recreational drug market in the United States after it became legal due to an ambiguity in the Agricultural Improvement Act 2018 (Farm Bill 2018). It was never legal outside the United States as the isomers of THC are regulated in the United Single Convention on Narcotic Drugs from 1971. HHC, a hydrogenated derivative of THC, followed as a legal substitute on the European recreational drug market. Many countries already placed HHC in their narcotic substance law, which led to the emergence of other structurally related derivatives of THC. An existing rapid screening method for the qualitative analysis of various new psychoactive substances was expanded for semi-synthetic cannabinoids in whole blood using a LC–QTOF–MS system. This method was validated for 24 different phytocannabinoids and semi-synthetic cannabinoids in blood. Recovery rates of the analytes from a liquid–liquid-extraction ranged from 87% to 118%, matrix effects ranged from 24% to 93%, and limits of detection (LOD) ranged from 0.8 to 16 ng/mL.


  • Recommendations for toxicological investigation of drug-impaired driving and motor vehicle fatalities—2025 update

    by Amanda L D’ORazio, Amanda L A Mohr, Ayako Chan-Hosokawa, Curt Harper, Marilyn A Huestis, Sarah Kerrigan, Jennifer F Limoges, Amy K Miles, Colleen E Scarneo, Karen S Scott, et al.

    This article describes updates to previously published recommendations for drug testing in drug-impaired driving cases. A survey of drug testing practices in driving under the influence of drug and motor vehicle fatality cases was sent to toxicology laboratories across the USA and Canada. Following the compilation of survey data, a virtual consensus meeting was held where forensic science practitioners and the authors reviewed the survey results and conducted a comprehensive review of the 2021 recommendations using a modified Delphi method. Tier I and Tier II screening and confirmation scope and cutoffs were re-evaluated to update the recommendations. Carisoprodol and meprobamate were moved to the Tier II scope from Tier I; gabapentin was promoted to the Tier I scope from Tier II; screening cutoffs were differentiated for immunoassay versus non-immunoassay (e.g. chromatographic) screening for blood and oral fluid; cross-reactivity screening requirements were removed and clarified with specific cutoff values; several cutoffs for screening and confirmation were increased or removed for blood and oral fluid; urine was removed as a recommended matrix for testing in cases involving suspected drug impairment.


  • Open Access

    Drug‐facilitated crime: A review of findings between 2019 and 2023

    by Meaghan R. Hessler, Sherri L. Kacinko, Barry K. Logan

    Drug‐facilitated crime (DFC) is a criminal act (e.g., assault, robbery, or sexual assault) in which the perpetrator uses drugs to impair the victim's ability to resist, remember, or recognize the crime being committed. Ethanol is commonly implicated in DFC casework, but limited data are published on other substances currently implicated in these crimes. DFC cases submitted to a large forensic reference laboratory between 2019 and 2023 were analyzed. Analytes and combinations were evaluated based on effect class. In total, 2371 blood samples and 5,041 urine samples were tested for common alcohols, GHB, and a variety of illicit and prescription medications. The most prevalent drug classes were cannabinoids (delta‐9‐THC/delta‐9‐THCCOOH), ethanol, and stimulants, with delta‐9 THC/metabolites being most prevalent in both matrices, followed closely by ethanol. The stimulant drug class's most prevalent analytes include methamphetamine, cocaine/cocaine metabolites, and amphetamine. Gamma‐hydroxybutyric acid (GHB) and flunitrazepam were infrequently detected. Polydrug combination data showed similar trends to when substances were identified alone, specifically that ethanol, cannabinoids, or a stimulant were often found in combination. Sedating substances were more prevalent than stimulating substances, specifically benzodiazepines and antihistamines. Polydrug data support urine collection in DFC cases, as they identified analytes in 22% of cases with negative blood toxicology. Recent literature notes novel psychoactive substances, including designer benzodiazepines, being detected in DFC cases globally, and recommends their inclusion in comprehensive DFC scopes. It is imperative that the appropriate matrix, scope, and limitations be evaluated to accurately determine trends, and scopes are continuously updated to capture the ever‐changing drug market.


  • Application of professional best practices in postmortem forensic toxicology

    by Michael T Truver, Chris W Chronister, Gregory G Davis, Teresa R Gray, Rebecca L Hartman, Joseph H Kahl, Erin L Karschner, Sarah Kerrigan, Robert Kronstrand, Alex J Krotulski, et al.

    Postmortem forensic toxicology plays a critical role in medicolegal death investigations through the identification and quantitation of drugs and other substances in postmortem fluids and tissues. Due to the complexity of this sub-discipline, consistent application of best practices is critical for ensuring accurate and reliable results, particularly in the context of challenges such as emerging novel psychoactive substances, complex poly-drug interactions, postmortem drug redistribution, and analytical limitations inherent with postmortem specimens. Although there has been significant progress in the development of consensus-based forensic toxicology standards, their scope is intentionally broad to accommodate human performance, postmortem, regulated and non-regulated employment drug testing, court-ordered toxicology, and other applications. Consequently, some aspects specific to postmortem toxicology and medicolegal death investigation are not addressed within the standards. This manuscript seeks to fill these gaps by demonstrating how current standards can be applied in a postmortem toxicology setting and presenting best practices in situations where no established standards exist. These best practices will aid laboratories in prioritizing changes to workflows, allocating resources more efficiently, improving analytical accuracy and reproducibility, ensuring interpretative consistency, and strengthening forensic defensibility in administrative and legal proceedings. Key topics addressed include specimen collection and case submission protocols, method validation approaches tailored for postmortem analysis, optimized analytical workflows based on testing scope and case classification, and quality assurance requirements. Considerations for data review, reporting, and result interpretation are discussed in the context of accurate determination of cause and manner of death. Emphasis is placed on integrating toxicological findings with investigative and autopsy information obtained through ongoing communication with stakeholders. By integrating the application of existing consensus standards with the best community practices for postmortem toxicology, this manuscript aims to support the generation of robust and reliable toxicological data, with the goal of improving forensic investigations, public health surveillance, and drug policy development.